BMO Capital Upgrades Regeneron Pharma (REGN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 flat as chipmakers fall and bank earnings roll in
- Oil prices mixed as US-Russia diesel deal hopes offset Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $752.85 -1.31%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 33
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 17 | New: 33
Join SI Premium – FREE
BMO Capital upgraded Regeneron Pharma (NASDAQ: REGN) from Market Perform to Outperform with a price target of $158.00 (from $143.00).
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $121.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial
- Regeneron Pharma (REGN) PT Raised to $810 at RBC Capital
- CIBC Upgrades Enerflex Ltd. (EFX:CN) (EFXT) to Outperformer
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
